hotronics, Inc. (NASDAQ: PLAB) paid approxi- mately $35 million to Micron Technology, Inc.
in connection with the purchase of its US nanoFab building in Boise, ID that it previously leased from the building’s owner Micron. In connection there- with, the Company also amended its credit facility adding a 5-year term loan for $25 million and redu- cing interest rates by 25 basis points on borrowings as defined in the credit facility.
Photronics is a leading worldwide manufacturer of photomasks.
Sivida Corp. (NASDAQ: PSDV) announced the positive outcome of the Decentralized Procedure (DCP) for the approval of ILUVIEN®
in Europe. The
regulatory process will now enter the national phase of the DCP in which the RMS and each CMS grants its national license. The CMS include Austria, France, Germany, Italy, Portugal and Spain. ILUVIEN will be indicated for the treatment of vision impairment as- sociated with chronic DME considered insufficiently responsive to available therapies.
pSivida has also entered into a technology evalua- tion agreement for its bioerodible Durasert™ drug delivery technology in ophthalmology with Neuron Systems, Inc., an ocular drug development company based in Burlington, USA. Under this agreement, the companies will evaluate the use of pSivida’s techno- logy as a delivery system for a treatment for dry age related macular degeneration (Dry AMD), a serious retinal disease that afflicts millions of patients world- wide and can lead to blindness.
VA TePla (TPEG), a German manufacturer of silicon crystallization systems, vacuum and high-
temperature systems, has published its preliminary results for fiscal 2011. The Company generated reve- nues of EUR132.6 million (previous year: EUR120.4 m). The rise in new orders to EUR156.2 million was particularly significant, resulting in correspondingly higher order backlog of currently EUR74.9 million as of December 31, 2011 (2010: orders of EUR93.4 million and order backlog of EUR52.9 million). For fiscal 2012 an EBIT margin of 8 to 10% is anticipa- ted.
D Vision, Inc. announced that Professor Ching Tang, inventor of the organic light emitting diode
(OLED) and a winner of the prestigious Wolf Prize in the field of chemistry, has joined the company’s scientific advisory board.
“While Wet AMD, which affects less than 20% of the population with AMD, is well treated with products such as Genentech’s billion dollar Lucentis and/or Regeneron’s Eylea, there currently is no approved treatment for Dry AMD, a disease which affects far more people,” said Dr. Paul Ashton, President and CEO of pSivida. Dr. Ashton added “this is the se- cond tech evaluation agreement pSivida has signed for its bioerodible Durasert technology since pSivida regained the rights to its intellectual property from Pfizer last year.”
12-02 :: February/March 2012